Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442
Summary of Product Characteristics last updated on the eMC: 27/01/2010
SPC Anafranil 75mg SR Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 27/01/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 6.2 - Incompatibilities
Date of revision of text on the SPC:   24-Nov-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



To update Section 4.5 of the SPC to include interaction with terbinafine.

To update Section 6.2 of the SPC to align with the Company Core Data Sheet.

Updated on 02/05/2008 and displayed until 27/01/2010
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   25-Mar-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

SECTIONS 4.4 and 4.8:

Updated to include suicidal thoughts and behaviour

Updated on 28/09/2006 and displayed until 02/05/2008
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   06/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

 
 SECTION 4.2:
  •     Paragraph on treatment discontinuation added
 SECTION 4.4:
  • Paragraph on "use in children and adolescents (0-17 years of age)" added
Updated on 27/09/2004 and displayed until 28/09/2006
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
Updated on 19/09/2003 and displayed until 27/09/2004
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 20/08/2001 and displayed until 19/09/2003
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 12/01/2001 and displayed until 20/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 12/01/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   clomipramine hydrochloride


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk